Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara van Zwieten

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Lancet (London, England)|August 25, 2004
Use of selective serotonin reuptake inhibitors in childhood depressionTamar Wohlfarth, Frits Lekkerkerker, Barbara van Zwieten
Lancet (London, England)|January 26, 2002
Informed consent from behaviourally disturbed patientsJitschak Storosum, Barbara van Zwieten, Lieuwe de Haan
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 16, 2008
A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressantsHans Melander, Tomas Salmonson, Eric Abadie, et al.
Lancet (London, England)|April 20, 2002
Placebo-controlled trials and the Declaration of HelsinkiJohn A Lewis, Bertil Jonsson, Gottfried Kreutz, et al.
Nature Reviews. Drug Discovery|August 2, 2012
DSM-5 and clinical trials in psychiatry: challenges to come?Florence Butlen-Ducuing, Manuel Haas, Luca Pani, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 27, 2009
Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concernsBenedetto Vitiello, Christoph Correll, Barbara van Zwieten-Boot, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2011
The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human UseZahra Hanaizi, Barbara van Zwieten-Boot, Gonzalo Calvo, et al.
The Oncologist|October 4, 2011
The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP)Petra Matt, Barbara van Zwieten-Boot, Gonzalo Calvo Rojas, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2013
The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human UseSilvy da Rocha Dias, Tomas Salmonson, Barbara van Zwieten-Boot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human UseMaria Nieto, Jeanett Borregaard, Jens Ersbøll, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Lancet (London, England)|August 25, 2004
Use of selective serotonin reuptake inhibitors in childhood depressionTamar Wohlfarth, Frits Lekkerkerker, Barbara van Zwieten
Lancet (London, England)|January 26, 2002
Informed consent from behaviourally disturbed patientsJitschak Storosum, Barbara van Zwieten, Lieuwe de Haan
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 16, 2008
A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressantsHans Melander, Tomas Salmonson, Eric Abadie, et al.
Lancet (London, England)|April 20, 2002
Placebo-controlled trials and the Declaration of HelsinkiJohn A Lewis, Bertil Jonsson, Gottfried Kreutz, et al.
Nature Reviews. Drug Discovery|August 2, 2012
DSM-5 and clinical trials in psychiatry: challenges to come?Florence Butlen-Ducuing, Manuel Haas, Luca Pani, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 27, 2009
Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concernsBenedetto Vitiello, Christoph Correll, Barbara van Zwieten-Boot, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2011
The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human UseZahra Hanaizi, Barbara van Zwieten-Boot, Gonzalo Calvo, et al.
The Oncologist|October 4, 2011
The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP)Petra Matt, Barbara van Zwieten-Boot, Gonzalo Calvo Rojas, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2013
The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human UseSilvy da Rocha Dias, Tomas Salmonson, Barbara van Zwieten-Boot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human UseMaria Nieto, Jeanett Borregaard, Jens Ersbøll, et al.
Pageof 2